Huntington National Bank lowered its stake in shares of Boston Scientific Co. (NYSE:BSX) by 9.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 18,306 shares of the medical equipment provider’s stock after selling 1,946 shares during the period. Huntington National Bank’s holdings in Boston Scientific were worth $705,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BSX. FMR LLC lifted its holdings in Boston Scientific by 10.4% during the second quarter. FMR LLC now owns 156,622,452 shares of the medical equipment provider’s stock worth $5,121,554,000 after buying an additional 14,711,069 shares during the period. Morgan Stanley lifted its holdings in Boston Scientific by 114.6% during the second quarter. Morgan Stanley now owns 7,517,384 shares of the medical equipment provider’s stock worth $245,818,000 after buying an additional 4,013,765 shares during the period. Epoch Investment Partners Inc. purchased a new stake in Boston Scientific during the second quarter worth $116,062,000. BlackRock Inc. increased its position in shares of Boston Scientific by 2.9% during the second quarter. BlackRock Inc. now owns 109,355,395 shares of the medical equipment provider’s stock worth $3,575,920,000 after purchasing an additional 3,062,924 shares in the last quarter. Finally, TD Asset Management Inc. increased its position in shares of Boston Scientific by 531.8% during the second quarter. TD Asset Management Inc. now owns 2,488,256 shares of the medical equipment provider’s stock worth $81,366,000 after purchasing an additional 2,094,436 shares in the last quarter. Institutional investors own 91.02% of the company’s stock.

A number of equities analysts have recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and set a $45.00 price target on shares of Boston Scientific in a research report on Tuesday, October 16th. Royal Bank of Canada upped their price target on Boston Scientific to $36.00 and gave the stock a “top pick” rating in a research report on Monday, July 23rd. Morgan Stanley upped their price target on Boston Scientific from $38.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 2nd. Sanford C. Bernstein assumed coverage on Boston Scientific in a research report on Wednesday, June 27th. They set an “outperform” rating and a $38.00 price target on the stock. Finally, Cowen set a $42.00 price target on Boston Scientific and gave the stock a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Boston Scientific presently has an average rating of “Buy” and an average target price of $38.70.

NYSE BSX opened at $36.62 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.60 and a current ratio of 0.83. Boston Scientific Co. has a 1 year low of $24.54 and a 1 year high of $39.44. The firm has a market capitalization of $50.53 billion, a P/E ratio of 26.29, a PEG ratio of 2.54 and a beta of 0.59.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.07. Boston Scientific had a return on equity of 26.35% and a net margin of 5.48%. The firm had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.47 billion. During the same period in the prior year, the firm earned $0.32 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. On average, analysts expect that Boston Scientific Co. will post 1.39 earnings per share for the current fiscal year.

In related news, EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $38.80, for a total value of $194,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP John Bradley Sorenson sold 10,000 shares of the company’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $35.86, for a total value of $358,600.00. Following the completion of the transaction, the senior vice president now directly owns 44,636 shares in the company, valued at $1,600,646.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 295,834 shares of company stock worth $11,038,468. 0.73% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.